Navigation Links
Europeans Developing First-Ever Dengue Fever Vaccine

Dengue fever is a viral infection transmitted through the bite of a mosquito. Symptoms can be mild with patients //never knowing they have been infected. However, in more unfortunate cases, Dengue fever can lead to haemorrhagic tendency triggering the often-fatal Dengue Shock Syndrome. Because some people experience only limited symptoms, they can unwittingly transport the virus from the tropics back to their home country. The Dengue virus increases the permeability of blood vessels causing blood loss leading to shock. An international research team claims to have identified the enzymes, which ultimately lead to blood loss, and have established an innovative treatment strategy. Their work was recently published in Nature’s EMBO Reports.

According to the team of international researchers from France, the UK and Thailand, approximately 60 to 100 million people are at risk of Dengue fever and the numbers are rising. A virus prevalent in areas also home to malaria, the most effective available prevention strategy is the elimination of the mosquito vector. In hopes of finding novel methods for eradicating the virus, the research team lead by the Institut de recherche pour le development (IRD) investigated the enzyme metalloproteinase and its effect on the cement holding blood vessels together.

They have uncovered evidence showing that metalloproteinase is responsible for effectively poking holes in the side of blood vessels by dissolving the proteins holding them together. Metalloproteinase is a naturally occurring compound involved in critical stages of embryo development and tissue repair. It has been shown to play a role in the development of certain cancers, however, and new evidence demonstrates that higher than normal concentrations can lead to haemorrhaging.

The research team was able to identify a direct relationship between cells infected by the Dengue virus and increased production of metalloproteinase. They crosschecked their findings against a series of cell cultures, and were able to confirm that raised levels of metalloproteinase were indeed responsible for the increased permeability of vascular tissue.

Once a protein inhibitor was introduced into the culture blocking the overactive metalloproteinase, natural permeability was restored. Their hypotheses concerning metalloproteinase were again supported through in vivo testing in mice.

The results uncovered by the European-led international team shed new light on Dengue’s pathological strategy. Researchers now suspect that they have not only come across a defence strategy for Dengue, but for a whole range of haemorrhage-inducing viruses, such as Ebola, Marburg, or Hanta, for none of which treatment exists. Clinical trials are currently being developed taking into account these new research strategies.

Source: Bio-Bio Technology
SR
'"/>




Related medicine news :

1. Vitamin D Deficiency On Rise Among Europeans
2. Europeans Tops the World in Alcohol Consumption
3. The Deadly Pair of Genes Increases the Risk of Breast Cancer among Europeans
4. Risk Of Developing Arthritis
5. Developing HIV fighter
6. Antibiotics Found To Increase The Risk Of Developing Breast Cancer
7. The Effectiveness Of Cancer Drug In Women At Risk Of Developing Cancer
8. Men Who at Risk Of Developing Prostate Cancer
9. Identifying The Risks Of Developing Schizophrenia
10. Patients With Severe Hemophilia At Risk Of Developing Osteoporosis
11. Cancer Patients At A Greater Risk Of Developing Blood Clots
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: